Relatlimab (Synonyms: BMS-986016) |
| カタログ番号GC66381 |
Relatlimab (BMS-986016) は、ヒト免疫グロブリンのミニ遺伝子座を持つトランスジェニック マウスを組換え LAG-3 タンパク質で免疫することによって生成されるヒト モノクローナル抗体抗 LAG-3 抗体です。 Relatlimab は、LAG-3/MHC II 相互作用を 0.67 nM の IC50 値でブロックし、LAG-3/FGL1 相互作用を 0.019 nM の IC50 値でブロックします。 Relatlimab は、がんの研究に使用できます。
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1673516-98-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer[1].
Relatlimab (BMS-986016; 0.001-100 nM) recognizes native LAG-3 and binds to primary activated human and cynomolgus CD4+ T cells with EC50 values of 0.11 nM and 29.11 nM, respectively[1].
Relatlimab (0.001-10000 nM; T cells (3A9-hLAG-3)) enhances peptide responsiveness of T-cell hybridoma 3A9-hLAG-3 and reversals LAG-3-mediated inhibition of T-cell hybridoma 3A9-hLAG-3 with an IC50 value of 1.05 nM[1].
Relatlimab (0.001-10000 nM; primary T cells) enhances activation of superantigen-stimulated human PBMC cultures and enhances IL-2 secretion[1].
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *